THE CURRENT UTILIZATION OF ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT AT NGHE AN ENDOCRINOLOGY HOSPITAL

Nguyễn Thị Cần; Phùng Khánh Duyên

doi:10.34238/tnu-jst.9000

THE CURRENT UTILIZATION OF ORAL MEDICATIONS FOR TYPE 2 DIABETES TREATMENT AT NGHE AN ENDOCRINOLOGY HOSPITAL

About this article

Received: 18/10/23 Revised: 05/01/24 Published: 03/02/24

Authors

1. Nguyen Thi Can, Vinh Medical University
2. Phung Khanh Duyen , Vinh Medical University

Abstract

The study aimed to investigate the current status of oral medication utilization for type 2 diabetes treatment at the Endocrinology Hospital of Nghe An province. The research employed a cross-sectional descriptive method, analyzing 96 medical records of all outpatient type 2 diabetes patients who were initially diagnosed at the Endocrinology Hospital of Nghe An and were under observation at the Department of Medical Examination from February 2023 to May 2023. The results showed that the medication profile for type 2 diabetes patients consisted of the following: the highest proportion was Biguanides (metformin) at 91.67%, followed by sulfonylureas (gliclazide) at 66.67%, DPP-4 inhibitors (vildagliptin) at 6.25%, and the lowest was the combination of metformin and vildagliptin at 2.08%. The prescribed treatment protocols included: single-drug therapy (37.50%), combination therapy with two drugs (56.25%), and combination therapy with three drugs (6.25%). Among them, 94 out of 96 patients (97.92%) were assigned appropriate treatment protocols.

Keywords

Type 2 diabetes; Medication for type 2 diabetes treatment; Endocrinology Department of Nghe An Hospital; Oral medications; Treatment protocol

Full Text:

PDF (Tiếng Việt)

References

[1] L. V. Wei et al., “Mechanisms and Characterristics of Sulfonylureas and Glinides,” Current Topics in Medicinal Chemistry, vol. 20, pp. 37-56, 2020.

[2] International Diabetes Federation, IDF Diabetes Atlas 10th, Belgium, 2021.

[3] J. Upadhyay et al., "Pharmacotherapy of type 2 diabetes: An update, Metabolism," Elsevier, vol. 78, pp. 13-42, 2018.

[4] L. Guariguata et al., “Global estimates of diabetes prevalence for 2013 and projections for 2035,” Diabetes Res Clin Pract, vol. 103, no. 2, pp. 137-149, 2014.

[5] J. C. Ozougwu, K. C. Obimba, C. D. Belonwu, and C. B. Unakalamba, “The pathogenesis and pathophysiology of type 1 and type 2 diabetes mellitus,” J Physiol Pathophysiol, no. 4, pp. 46-57, 2013.

[6] Institute of Health Metrics and Evaluation, “What causes the most deaths?” Heath reserch by location: Vietnam, 2017. [Online]. Available: http://www.healthdata.org/vietnam. [Accessed Jan 15, 2023].

[7] C. D. Mathers and Loncar, “Projections of global mortality and burden of disease from 2002 to 2030,” PLoS Med, vol. 11, no. 3, p. 442, 2006.

[8] Stumvoll, M. Goldstein, and J. van Haeften, “TW Type 2 diabetes: principles of pathogenesis and therapy,” Lancet, vol. 365, pp. 1333-1346, 2005.

[9] Weyer, C. Bogardus, C. Mott, and D. M. Pratley, “RE The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus,” J. Clin Invest, vol. 104, pp. 787-794, 1999.

[10] H.T.N, “Self-care knowledge of the lost control diabetes patients outpatient treatment in Thai Nguyen center Hospital 2019”, (in Vietnamese), TNU Journal of Science and Technology, vol. 225, no. 1, p. 79-86, 2020.

[11] Ministry of Health, Issued together with Decision No. 5481/QD-BYT, Guidelines for the Diagnosis and Treatment of Type 2 Diabetes, December 30, 2020.

[12] S. E. Inzucchi, "Is It Time to Change the Type 2 Diabetes Treatment Paradigm? No! Metformin Should Remain the Foundation Therapy for Type 2 Diabetes," Diabetes Care 2017 Aug, vol. 40, no. 8, pp. 1128-1132, 2017.

[13] M . H. T. Nguyen, "Analysis of the use of type 2 diabetes treatment medications in outpatient settings at the Nam Tu Liem District Health Center, Hanoi,"(in Vietnamese), Thesis for the Specialist Pharmacist Degree I, Hanoi University of Pharmacy, 2016.

[14] H. A. Nguyen, "Evaluation of Medication Use in Type 2 Diabetes Patients at the Department of Internal Medicine, E Hospital," Graduation Thesis, University of Pharmacy, Hanoi, 2021.

[15] American Diabetes Association, “Standards of Medical Care in Diabetes—2022 Abridged for Primary Care Providers,” Clinical Diabetes, vol. 40, no. 1, p. 4, 2022.

[16] Ziquan Lv and Yajie Guo. "Metformin and Its Benefits for Various Diseases," Front Endocrinol (Lausanne), vol. 191, no. 11, p. 1, 2020.

[17] H. T. H. Luong et al., "Survey on the Use of Medications for Type 2 Diabetes Treatment in Outpatients at Long Xuyen City Health Center in 2019," (in Vietnamese), Journal of Vietnamese Medicine, vol. 524, no. 2, p. 108, 2019.

[18] B. B. Tran et al., "Survey on the Use of Medications for Type 2 Diabetes Treatment in Elderly Outpatients at the Endocrinology Clinic, Ho Chi Minh City University of Medicine and Pharmacy," (in Vietnamese), Diabetes Endocrinology & Metabolism Association of Central Vietnam, vol. 28, 2021. [Online]. Available: https://demacvn.com/khao-sat-tinh-hinh-su-dung-thuoc-dieu-tri-dai-thao-duong-type-2-tren-benh-nhan-cao-tuoi-dieu-tri-ngoai-tru-tai-phong-kham-noi-tiet-benh-vien-dai-hoc-y-duoc-thanh-pho-ho-chi-minh/. [Accessed Jan. 13, 2023].

[19] Hospital C Da Nang, "Diabetes in the Elderly," 2020. [Online]. Available: https://bvcdn.org.vn/2020/01/15/dai-thao-duong-o-nguoi-cao-tuoi/. [Accessed Jan. 13, 2023].

DOI: https://doi.org/10.34238/tnu-jst.9000

Refbacks

There are currently no refbacks.



Remember me